Sam Bird
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- SARS-CoV-2 and COVID-19 Research 2
- Journals
- The Lancet (6 papers)The Lancet Respiratory Medicine (1 paper)Journal of Foot and Ankle Research (1 paper)
- Partner nations
- United KingdomAustraliaIndonesia
In The Last Decade
Sam Bird
8 papers receiving 1.5k citations
Sam Bird's Hit Papers
Peers
Comparison fields: 5 of 99
- Infectious Diseases 963
- Applied Microbiology and Biotechnology 50
- Neurology 343
- Internal Medicine 56
- Obstetrics and Gynecology 85
Countries citing papers authored by Sam Bird
This map shows the geographic impact of Sam Bird's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sam Bird with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sam Bird more than expected).
Fields of papers citing papers by Sam Bird
This network shows the impact of papers produced by Sam Bird. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sam Bird. The network helps show where Sam Bird may publish in the future.
Co-authors
The 2 scholars most cited alongside Sam Bird, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 6 | 2023 | 83 | |
| 7 | 2023 | 16 | |
| 8 | 2023 | 1 |
About Sam Bird
Sam Bird is a scholar working on Infectious Diseases, Insect Science, Renewable Energy, Sustainability and the Environment, Obstetrics and Gynecology and Anesthesiology and Pain Medicine, having authored 8 papers that have together received 1.6k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (2 papers). The work is most often cited by research in Infectious Diseases (963 citations), Applied Microbiology and Biotechnology (50 citations), Neurology (343 citations), Internal Medicine (56 citations) and Obstetrics and Gynecology (85 citations). Sam Bird has collaborated with scholars based in United Kingdom, Australia and Indonesia. Frequent co-authors include Yeliz Prior and Christopher Nester. Their work appears in journals such as The Lancet, The Lancet Respiratory Medicine and Journal of Foot and Ankle Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.